Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.

Raje, N; Hideshima, T; Mukherjee, S; Raab, M; Vallet, S; Chhetri, S; Cirstea, D; Pozzi, S; Mitsiades, C; Rooney, M; Kiziltepe, T; Podar, K; Okawa, Y; Ikeda, H; Carrasco, R; Richardson, P G; Chauhan, D; Munshi, N C; Sharma, S; Parikh, H; Chabner, B; Scadden, D; Anderson, K C

Raje, N; Hideshima, T; Mukherjee, S; Raab, M; Vallet, S; Chhetri, S; Cirstea, D; Pozzi, S; Mitsiades, C; Rooney, M; Kiziltepe, T; Podar, K; Okawa, Y; Ikeda, H; Carrasco, R; Richardson, P G; Chauhan, D; Munshi, N C; Sharma, S; Parikh, H; Chabner, B; Scadden, D; Anderson, K C.

Affiliation

Raje N; Division of Hematologic Malignancies, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02114, USA. nraje@partners.org

Leukemia ; 23(5): 961-70, 2009 May.

Article in En | MEDLINE | ID: mdl-19151776

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cyclin D1 / Flavones / Multiple Myeloma / Antineoplastic Agents Type of study: Prognostic_studies Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2009 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google